DNLI Q3 2020 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-31.0% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$60M-640.0% margin

Net Income

-$58M-619.9% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+60.6%

Cash Flow

Operating Cash Flow

$86,000

Free Cash Flow

-$620,000

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$188M

Stockholders' Equity

$883M

Cash & Equivalents

$351M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$14M	-31.0%
Gross Profit	$9M	$14M	-31.0%
Operating Income	-$60M	-$50M	-19.9%
Net Income	-$58M	-$46M	-25.9%

Revenue Segments

Alzheimer's Disease Services

$3M100%